EMA Application withdrawn: Livmarli (Maralixibat chloride) — FGK Representative Service GmbH

View source ↗

Summary

The EMA has withdrawn the application for Livmarli (maralixibat chloride) represented by FGK Representative Service GmbH.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cholestasis
• Intrahepatic Cholestasis

Drugs mentioned

• LIVMARLI (Maralixibat chloride)

Snippet

Status: Application withdrawn. Therapeutic area: Cholestasis, Intrahepatic. MAH: FGK Representative Service GmbH. Orphan medicine